Stay updated with breaking news from Peter Heerma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average […]
Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Equities researchers at HC Wainwright cut their FY2028 earnings estimates for Travere Therapeutics in a report issued on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will earn $4.29 per share for the year, down from their previous estimate of $4.66. HC […]
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its price target lifted by HC Wainwright from $17.00 to $19.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 248.62% from the company’s […]
Operator: Good day and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, February 15th. Analysts expect Travere Therapeutics to post earnings of ($1.27) per share for the quarter. Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 7th. […]